A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis (ROSETTA)

AnaptysBio

Status and phase: Enrolling; Phase 2

Conditions: Ulcerative Colitis

Treatments: Drug: Placebo; Drug: Rosnilimab

Study type: Interventional

Funder types: Industry

Identifiers

NCT06127043

ANB030-204 ROSETTA

Details and patient eligibility

About

ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)

Full description

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of rosnilimab in subjects with moderate to severe ulcerative colitis (UC).

Enrollment: 132 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female ≥18
• Participants with a clinical diagnosis of UC for prior to Day 1
• Subject has moderate to severe, active UC, defined as a mMS ≥ 5 with an endoscopy subscore ≥2
• Subject has had a surveillance colonoscopy that did not detect potential dysplasia or colon cancer performed within 1 year of Day 1.
• Subject has a history of an inadequate response, loss of response, or intolerance to any combination of at least 2 UC therapy classes defined as, but not limited to, aminosalicylates, corticosteroids, immunomodulators, calcineurin inhibitors, or advanced UC therapies (e.g., biologics, JAK inhibitors, oral S1P receptor modulators, etc.)

Exclusion criteria

• Subject has a diagnosis of Crohn's disease or indeterminate colitis.
• Subject has a diagnosis of fulminant colitis and/or toxic megacolon.
• Subject has a history of an inadequate response, loss of response, or intolerance to any combination of 3 or more advanced UC therapy classes but not limited to, 1) anti-TNF antibodies (e.g., adalimumab, golimumab, infliximab), 2) other biologics (e.g., ustekinumab, vedolizumab), 3) oral JAK inhibitors (e.g., tofacitinib, upadacitinib), and 4) oral S1P receptor modulators (e.g., ozanimod).
• Subject has disease limited to the rectum (ulcerative proctitis)
• Subject has a history of colectomy (total or subtotal), ileoanal pouch, Kock pouch, or ileostomy or is planning bowel surgery.
• The subject had prior exposure to a PD-1 or PD-L1 agonist, antagonist, or modulator.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

132 participants in 3 patient groups, including a placebo group

Rosnilimab SC Dose 1

Experimental group

Description:

This arm will receive High dose Rosnilimab SC

Treatment:

Drug: Rosnilimab

Rosnilimab SC Dose 2

Experimental group

Description:

This arm will receive low dose Rosnilimab SC

Treatment:

Drug: Rosnilimab

Placebo

Placebo Comparator group

Description:

This arm will receive Placebo SC

Treatment:

Drug: Placebo